Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US

publication date: Feb 28, 2023

Shanghai Oricell Therapeutics closed a $45 million B1 investment round to develop its portfolio of cellular immunotherapies, particularly in the US. In July 2022, the company completed a $120 million B round. Oricell plans to take OriCAR-017, a GPRC5D CAR-T therapeutic that treats relapsed and refractory multiple myeloma, to the US as the lead drug in its US expansion. The candidate is in IND enabling studies in the US and China. The B1 round was led by RTW Investments and Qatar Investment Authority with participation from existing investors Qiming Venture Partners and C&D Emerging Industry Equity Investment. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital